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ABSTRACT: A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid 
toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity 
against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium 
falciparum. Structure-activity relationship studies led to the identification of highly promising 
analogs, the most potent of which had IC50s in the nanomolar range against both strains. The 
compounds further demonstrated good in vitro microsomal metabolic stability while those 
subjected to in vivo pharmacokinetic studies had desirable pharmacokinetic profiles. In vivo 
antimalarial efficacy in Plasmodium berghei infected mice was evaluated for four compounds, all 
of which showed good activity following oral administration. In particular, compound 19 
completely cured treated mice at a low multiple dose of 4×10 mg/kg. Mechanistic and 
bioactivation studies suggest hemozoin formation inhibition and a low likelihood of forming 
quinone-imine reactive metabolites, respectively. 
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1. INTRODUCTION 
Malaria remains a leading cause of morbidity and mortality globally. In 2012, there were an 
estimated 207 million cases of malaria and 627 000 deaths worldwide, with 90% of all malaria 
deaths occurring in sub-Saharan Africa.1 One of the biggest challenges facing malaria 
chemotherapy is the rapid emergence of resistance to existing antimalarial drugs.2 This challenge 
underscores the need for the continued search for new antimalarials.  
Chloroquine (1) (structure shown in Figure 1),  was undoubtedly one of the most successful 
antimalarials ever owing to its good efficacy and low cost which made it affordable especially in 
the developing countries with high malaria endemicity.3 Chloroquine was replaced as first line 
therapy by the sulfonamide antimalarials and, later on, artemisinin combination therapy (ACT), 
following the development of widespread resistance against the drug by Plasmodium falciparum.4 
An aromatic side chain analogue of chloroquine, amodiaquine (2), however, retains activity against 
chloroquine-resistant Plasmodium strains.5 Besides, it is an established fact that resistance against 
these 4-aminoquinolines is not a result of target modification but is caused by impaired 
accumulation of the drug at the target.6,7 Consequently, amodiaquine is an attractive lead 
compound in the search for new antimalarials. Despite the desirable antimalarial efficacy of 
amodiaquine, chronic use especially during prophylaxis has been found to precipitate severe 
hepatotoxicity, myelotoxicity and agranulocytosis.8,9 This toxicity has been attributed to the 
bioactivation of amodiaquine to reactive quinone imine (3) and aldehyde quinone imine (4) 
metabolites (figure 1) which covalently bind to cellular macromolecules causing drug-induced 
toxicity and cell damage directly or via immunological mechanisms.10–12  
<<figure 1>> 
The avoidance of amodiaquine bioactivation has been the subject of a number of previous studies. 
Park and co-workers have demonstrated that the 4′-hydroxyl group of amodiaquine could be 
replaced with a 4′-fluorine atom to produce 4'-dehydroxy-4'-fluoroamodiaquine (5) with 
antimalarial activity in the low nanomolar range.11,13 Miroshnikova and coworkers synthesized 
various isotebuquine analogs (6) with excellent antimalarial activity but poor oral bioavailability.14 
The most successful campaign towards circumventing amodiaquine bioactivation was the 
synthesis of isoquine (7) and its analogues by O'Neill and co-workers.15 One of these analogues, 
N-tert-butyl isoquine (8), progressed to clinical trials but its development has been discontinued 
due to exposures insufficient to demonstrate drug safety superior to chloroquine.16–18 Figure 2 
shows the chemical structures of some of the compounds synthesized to circumvent amodiaquine 
bioactivation. 
<<figure 2>> 
In a previous paper, we reported for the first time the synthesis and potent antiplasmodial activity 
of benzothiazolyl (9-13), benzimidazolyl (14-17), benzoxazolyl (18-19) and pyridyl (20-21) 
analogues of amodiaquine (figure 3) designed to prevent bioactivation to both the quinone imine 
and aldehyde metabolites.19 The present paper reports on the bioactivation studies on these 
compounds and the selection, expanded synthesis and structure activity relationship (SAR) studies 
of the benzoxazole analogues. The in vitro antiplasmodial, mechanistic and metabolic stability 
evaluation as well as in vivo pharmacokinetic and efficacy studies on this class of compounds is 
presented. 
<<figure 3>> 
Bioactivation potential can be evaluated using various approaches including covalent binding 
studies and trapping with different reagents following incubation with microsomes or 
hepatocytes.20 The trapping reagents used include glutathione (for soft electrophiles such as the 
quinone imine) as well as methoxylamine and potassium cyanide (for hard electrophiles such as 
the iminium ion).21–23 Electrochemical oxidation online with electrospray ionization mass 
spectrometry (EC-ESI/MS) is a relatively new technique that avoids the complexity of working 
with biological matrices. Electrochemical oxidation has been found to successfully mimic CYP450 
benzylic hydroxylation, hydroxylation of aromatic rings containing electron-donating groups, N-
dealkylation, S-oxidation, dehydrogenation and, less efficiently, N-oxidation and O-
dealkylation.24 Johansson and co-workers have demonstrated the utility of electrochemical 
oxidation to mimic CYP450 and liver microsome catalyzed oxidation of amodiaquine and 
desethylamodiaquine.25 Other researchers have employed electrochemistry to mimic phase I 
oxidation of paracetamol, clozapine, trimethoprim and diclofenac.26,27 The coupling of EC with 
MS means that MS/MS can be used to provide important structural information about the reactive 
metabolites formed. 
2. RESULTS AND DISCUSSION 
2.1. Bioactivation studies on previously synthesized analogues 
The bioactivation potential of our previously synthesized analogues 9-21 was evaluated using 
trapping experiments involving glutathione, potassium cyanide and methoxylamine. The EC-
ESI/MS system was utilized whereby mass spectra were scanned for the presence of adduct peaks 
arising from covalent bond formation between any reactive intermediates produced (upon 
oxidative bioactivation) and the trapping agents. 
The results of the glutathione trapping experiment were semi-quantitatively expressed as the ratio 
of the sum of test compound adduct peak areas to clozapine adduct peak area and were represented 
graphically (figure 4). Clozapine is commonly used as a model compound that undergoes 
bioactivation to a nitrenium intermediate which, in turn, readily forms a glutathione conjugate.28,29 
A value of zero implies that no adduct was detected for the test compound while a value greater 
than one implies the sum of adduct peak areas for the test compound is greater than the area of the 
clozapine adduct peak. This implies that the compound has a higher potential for bioactivation 
than clozapine. Our study demonstrated that benzoxazole analogues 18 and 19 had the lowest 
potential for bioactivation to the quinone imine metabolite.30 Benzothiazole analogues 9, 11 and 
12 had the largest glutathione ratios (0.74, 0.88 and 1.13, respectively) and hence the highest 
potential for bioactivation to soft electrophilic metabolites. The proposed bioactivation 
mechanisms, facilitated by the more nucleophilic nitrogen and sulphur atoms, to quinone-like 
intermediates for the benzothiazolyl, benzimidazolyl and pyridyl series are shown in figure 5.  
<<figure 4>> 
<<figure 5>> 
Results for the trapping of hard electrophiles using potassium cyanide and methoxylamine were 
expressed as positive or negative depending on the detection or lack thereof, respectively, of 
cyanide and methoxylamine adduct peaks in the spectra of the test compounds (figure 4). The 
benzothiazole tert-butyl side chain analogue 9, the benzimidazole ethyl side chain analogue 14 
and the benzoxazole ethyl side chain analogue 18 did not undergo trapping with either reagent. 
We concluded that trapping was purely dependent on the nature of the side chain, such that only 
molecules with a highly basic tertiary amine on the side chain could form reactive species capable 
of reacting with potassium cyanide and methoxylamine. Such an observation can be explained 
using the well known metabolic pathway for tertiary amines which involves formation of iminium 
ions and aldehydes.31 Our previous results (table 1) had shown that a highly basic tertiary amine 
side chain gave the most potent antiplasmodial activity. Thus a functional group considered 
essential for activity was also involved in bioactivation. However, the aldehyde metabolite of 
amodiaquine is conjugated with the aminophenol ring and, therefore, relatively stable. The 
aldehyde metabolite formed by these compounds is attached to the benzoxazole nucleus via a labile 
amino group. The low bioactivation potential of the benzoxazole series in the glutathione trapping 
experiment made this series attractive for further exploration.  
<<Table 1>> 
2.2. Chemistry 
The synthesis of novel benzoxazoles 22-41 starting with 2-amino-4-nitrophenol, carried out as 
previously described, is shown in scheme 1.19 Novel analogues 42 and 43 were synthesized by a 
one step coupling of appropriately substituted commercially available benzoxazole-5-amines with 
4,7-dichloroquinoline. 
<<scheme 1>> 
2.3. In vitro antiplasmodial activity 
The two previously reported benzoxazole analogues (18 and 19) and the newly synthesized 
analogues 22-43 were tested against the chloroquine-sensitive NF54 and the multidrug resistant 
K1 strains of Plasmodium falciparum. Results are presented in table 2.  Selected intermediate 
compounds were tested alongside the target compounds and the results of these are presented in 
the Supporting Information (SI Table 1).  
<<table 2>> 
The most potent compounds 19, 23, 24, 27, 28 and 29 had IC50 values equal to or comparable to 
that of chloroquine (0.001 µM) against the chloroquine-sensitive NF54 strain (Table 2). These 
potent compounds were all dialkylamino or cycloalkylamino analogues with a highly basic tertiary 
nitrogen and could be classified as either ethylamino (19, 23, 27 and 29) or propylamino (24, 26, 
28 and 30) linker analogues.  Activity against the NF54 strain did not vary widely, ranging between 
0.001 and 0.019 µM, except for the morpholino analogues. The ethylmorpholino analogue 25 was 
the least active compound against the NF54 strain among the highly basic tertiary nitrogen 
analogues (IC50 = 0.108 μM), followed by the propylmorpholino analogue 26 (IC50 = 0.039 μM). 
Variations from which a tentative SAR could be derived were noticeable in K1 activity. Changing 
the dialkylamino group from diethyl to dimethyl did not have any effect on activity in ethylamino 
linker analogues as both 27 and 29 had an IC50 of 0.042 μM. Changing to a propylamino linker 
resulted in the diethyl analogue 28 (IC50 = 0.085 μM) being more potent than the dimethyl 
analogue 30 (IC50 = 0.149 μM). A similar trend was observed for the piperidine analogues where 
the ethylpiperidine compound 23 (IC50 = 0.024 μM) was more active than the propylpiperidine 
analogue 24 (IC50 = 0.039 μM). However, this trend was reversed among the morpholino 
analogues 25 and 26 mentioned earlier where the propylamino linker analogue was the more potent 
analogue. Converting the tertiary amine to an amide, as in 22, resulted in a drastic decline in 
activity against both strains, more so against the NF54 (IC50 = 1.876 μM) than the K1 (IC50 = 0.773 
μM) strain. These results underscored the importance of the highly basic nitrogen.  
Further exploratory studies involved the synthesis of analogues in which the side chain was 
attached to the benzoxazole group via a carbon instead of a nitrogen atom (Table 2). Although 
analogue 42 had a highly basic nitrogen, it showed remarkably reduced activity against both strains 
(NF54 IC50 = 0.213 μM, K1 IC50 = 0.411 μM) compared to the alkylamino or cycloalkylamino 
analogues. The reduction in activity could not simply be accounted for by the low predicted pKa 
(7.75) since the morpholino analogues with even lower pKas showed better activity. Attachment 
to the benzoxazole ring via a carbon atom was, therefore, considered to adversely affect 
antiplasmodial activity. Analogue 43 only exhibited micromolar activity (NF54 IC50 = 1.094 μM, 
K1 IC50 = 2.111 μM), probably due to the presence of a carbon linker and the lack of a highly basic 
nitrogen.  
When the alkylamino groups were replaced with substituted benzylamines (31 and 32), activity 
dropped to the low submicromolar range. The benzylamine analogues were less active than 
chloroquine against the NF54 strain and virtually equipotent with the drug against the K1 strain. 
The methylpyridine analogues (33, 35 and 36) had activity in the mid-submicromolar to low 
micromolar range with activity increasing in the order 4-methyl < 2-methyl < 3-methyl. Increasing 
the length of the linker from a methyl to an ethyl as in 34 did not affect activity when compared to 
the corresponding 2-methylpyridine analogue 33. As with the rest of the analogues discussed 
above, these compounds were more active against the chloroquine-sensitive NF54 strain as 
compared to the multidrug-resistant K1 strain.  
Among the piperazinyl linker analogues, the methylpiperazine analogue with the piperazine ring 
directly attached to the benzoxazole ring 39 was more active than the corresponding 1-amino-4-
methylpiperazinyl analogue 37. Indeed 39 retained activity against the multidrug-resistant K1 
strain (IC50 = 0.099 μM). Attachment of aromatic groups to the piperazine linker (40 and 41) 
resulted in further loss of activity against both the NF54 and K1 strains. The chloro substituted 
phenyl ring in 41 resulted in a two-fold improvement in activity against the K1 strain (IC50 = 0.412 
μM) over 36 with an unsubstituted phenyl ring (IC50 = 0.875 μM). In all cases, the pattern of 
sensitivity observed with the other analogues was maintained. In terms of structure, analogue 38 
was a homologue of the diethylamino analogues 27 and 28. The reduced activity of 38 shows the 
importance of the aminoalkyl linker in the antiplasmodial potency of these compounds. 
Whereas all the intermediates tested were considered inactive (IC50>20 μM), intermediate 19d 
with a highly basic tertiary nitrogen showed low micromolar activity against both plasmodial 
strains (SI Table 1). Overall, these findings pointed to the fact that the quinoline ring was essential 
for antiplasmodial activity. Compounds with potent antiplasmodial activity exhibited good 
selectivity for Plasmodium  falciparum over Chinese hamster ovary cells as seen from the high 
selectivity indexes in table 2. 
2.3. β-Hematin inhibition studies 
The two previously reported benzoxazole analogues (18 and 19) and the newly synthesized 
analogues 22-43 were subjected to the β-hematin inhibition assay using a previously described 
procedure32 in an attempt to establish whether or not these compounds exert their antiplasmodial 
effect similarly to other 4-aminoquinolines. The results of the β-hematin inhibition assay (table 2) 
were correlated with the antiplasmodial activity against the NF54 strain in which resistance 
mechanisms that impair drug accumulation are not yet established. The cycloalkylamine 
compounds 19, 23, 24, 25 and 26 had IC50 values of between 80.0 and 105.0 μM. The dialkylamine 
analogues 27-30 were less potent inhibitors of β-hematin formation (IC50s = 165.0-244.2 μM). 
Ethyldialkylamine analogues 27 and 29 (IC50 = 244.2 and 363.2 μM, respectively) had lower 
activity compared to the propyldialkylamine analogues 28 and 30 (IC50 = 165.0 and 173.7 μM, 
respectively).  Overall, there was a lack of correlation between β-hematin inhibition and 
antiplasmodial activity against the NF54 strain as illustrated by the observation that compounds 
with the most potent β-hematin inhibition did not exhibit the most potent antiplasmodial activity. 
This lack of correlation may imply that the compounds exert their antiplasmodial effect through 
additional mechanisms or that the compounds do not accumulate in the acidic food vacuole 
efficiently. The non-quinoline benzoxazole intermediates did not show any inhibitory activity even 
at the highest concentration of 1000 μM (data not tabulated). Thus it can be concluded, as expected, 
that the quinoline ring is essential for the β-hematin inhibition observed in this series of 
compounds. 
A statistically significant linear correlation was found between the logP of the compound with the 
inverse of the β-hematin inhibition activity (data supplied in SI Table 2) (figure 6). An increase in 
logP was found to improve β-hematin inhibition activity according to the equation 1/βHIC50 = 
0.0084(logP) – 0.02, r2=0.65, p < 0.0001, statistically significant at the 95% confidence level. This 
correlation suggests that compounds with greater logP have higher potency for preventing the 
growth of β-hematin crystals. Such compounds have an additional aromatic phenyl ring on the 
benzoxazole end of the molecule. Furthermore, compounds with the highest inhibitory activity 
possess inductively electron withdrawing (EW) substituents on the phenyl ring (Cl, CF3). This may 
contribute favourably to the widely accepted π-π-stacking phenomenon for quinolines, whereby 
the molecule prevents -hematin crystallization growth via a π-π interaction with a face of the 
hemozoin crystal.33 Hence, the extra ring, in particular one with an EW substituent, may strengthen 
the molecule’s interaction with heme, resulting in increased activity. However, since analogues 
with an extra aromatic ring did not have a highly basic tertiary amine, they may not accumulate as 
efficiently as highly basic tertiary amines in the parasitic food vacuole where these compounds are 
believed to act.  
 
<<figure 6>> 
 
2.4. In vitro microsomal metabolic stability studies 
Microsomal metabolic stability was evaluated using a single-time-point assay in which the 
percentage of parent compound remaining after 30 minutes incubation of the test compound in the 
presence of pooled human liver or mouse liver microsomes (HLMs or MLMs) and NADPH was 
determined.34 The two previously reported benzoxazole analogues (18 and 19) and the newly 
synthesized analogues 22-43 were evaluated. Microsomal stability results are presented in figure 
7. Ethyl side chain analogue 18 was extremely unstable in MLMs but very stable in HLMs. The 
most stable compound was the dimethylamino analogue 29. This analogue was virtually not 
metabolized in MLMs and HLMs after 30 minutes of incubation. Propylmorpholino analogue 26 
was the least stable analogue with <30% remaining after 30 minutes of incubation with both MLMs 
and HLMs. Ethyldialkylamino analogues 27 and 29 were observed to be more metabolically stable 
than the corresponding propyldialkylamino analogues 28 and 30, respectively. This may be 
construed to imply that the propyl linker is the source of metabolic lability. The methylpiperazine 
analogue 39 was moderately stable in HLMs but unstable in MLMs, with only 18 % of the 
compound remaining after 30 minutes. Except for 19 and 41, the analogues were generally more 
stable in HLMs than in MLMs. Overall, benzoxazole analogues with potent antiplasmodial activity 
(19, 23, 24, 27 and 29) exhibited metabolic stability equal to or greater than amodiaquine in HLMs. 
In MLM incubations, the analogues were at least twice as stable as amodiaquine except for 23 with 
only 41 % of the parent compound remaining after 30 minutes. It was apparent that in MLMs the 
metabolic stability of the cycloalkylamino compounds decreased in the order morpholine 
analogues > pyrrolidine analogues > piperidine analogues. 
<<figure 7>> 
2.5. In vivo pharmacokinetic studies 
The pharmacokinetic evaluation of compound 24 was performed in C57Bl/6 mice following oral 
and intravenous administration, n = 3 over 24 hours. Linear and semi-log plots are shown in figure 
8. Non-compartmental analysis was performed and the results given in table 3. Compound 24 had 
good bioavailability of 56% and was defined as having low clearance, assuming low clearance to 
be below a third of the average mouse liver blood flow of 90 mL/min/kg,35 while the volume of 
distribution was high at 24.5 L/kg resulting in a long elimination half-life of approximately 10 
hours. Compound 24 was absorbed at a moderate rate with Tmax at approximately 3 hours. The 
high volume of distribution and low clearance suggests the compound accumulates in secondary 
compartments and is slowly released back into blood, increasing in vivo efficacy and mean survival 
days. The low clearance observed in vivo for 24 is not consistent with the observed in vitro 
metabolic depletion rates for this series of compounds which may point to the role of other factors 
such as high microsomal and plasma protein binding affecting drug elimination. 
 
<<figure 8>> 
<<table 3>> 
 
2.6. In vivo efficacy studies 
The in vivo antimalarial efficacy of four of the most promising compounds was evaluated using a 
P. berghei mouse model by determining parasitemia reduction and mean survival days (MSD) for 
single- or multi-dose regimens. The results, following oral (p.o.) administration, for test 
compounds 19, 23, 24 and 29 as well as the antimalarial drugs chloroquine and amodiaquine, are 
summarized in table 4.  At the highest oral doses (4×50 mg/kg), all the compounds displayed 
excellent parasitemia reduction (>99.8%). Compound 19, which was among the initial sets of 
compounds synthesized, afforded complete cure with all six treated mice surviving through the 
entire 30 day period without any signs of toxicity. Five out of six mice treated with 24 were 
completely cured with all six mice attaining 30 mean survival days. Compound 29, the dimethyl 
analog with good in vitro microsomal stability also exhibited potent activity achieving 29.3 mean 
survival days (2 out of 3 mice cured) while mice treated with 23 survived for an average of 27 
days (1 out of 3 mice cured). The three best performing compounds were further tested at a single 
oral dose of 50 mg/kg and all compounds showed >99% parasitemia reduction. Compound 19 was 
the most potent (23.3 MSDs) while 24 (14.0 MSDs) and 29 (13.7 MSDs) were virtually equipotent. 
When these three compounds were subjected to a low multi-dose oral regimen of 4 × 10 mg/kg, 
potent parasitemia reduction (>99%) was maintained. Remarkably, 19 afforded complete cure 
(>30 MSDs) at this low dose making it the most promising compound in this series. Compound 
29 was the second most potent (24 MSDs, 1 out of 3 mice cured) while 24 (15.7 MSDs) gave the 
lowest survival rate. 
<<table 4>> 
3. CONCLUSION 
A novel series of orally active antimalarial benzoxazole-4-aminoquinolines has been identified. 
The compounds in this series demonstrated potent in vitro antiplasmodial activity against both 
chloroquine-sensitive and drug-resistant Plasmodium falciparum strains and good in vivo efficacy 
in a murine malaria model. The compounds showed promising microsomal stability and an 
attractive pharmacokinetic profile. Preliminary mechanistic studies pointed to  inhibition of β-
hematin formation as one possible mechanism of action for these compounds, with the lack of 
strong correlation between inhibition and antiplasmodial activity suggesting that other 
mechanisms of action may be involved. The compounds circumvented bioactivation to the quinone 
imine and the relatively stable aldehyde metabolite of amodiaquine. Compound 19 combines good 
in vitro activity against P. falciparum with oral efficacy in a P. berghei mouse model. 
 
 
 
 
4. EXPERIMENTAL 
4.1. Chemistry 
4.1.1 . General remarks 
All commercially available chemicals were purchased from either Sigma-Aldrich or Combi-
Blocks. All solvents were dried by appropriate techniques. Unless otherwise stated, all solvents 
used were anhydrous. 1H NMR spectra were recorded on a Varian Mercury Spectrometer at 300 
MHz or a Varian Unity Spectrometer at 400 MHz with Me4Si as internal standard. 
13C NMR 
spectra were recorded at 75 MHz on a Varian Mercury Spectrometer or at 100 MHz on Varian 
Unity Spectrometer with Me4Si as internal standard. Spectra were recorded at ambient 
temperature, unless otherwise stated. Chemical shifts () are reported in parts per million 
downfield from Me4Si and referenced to residual solvent. Standard abbreviations indicating 
multiplicity are used as follows: br s = broad, d = doublet, m = multiplet, q = quartet, quint. = 
quintet, s = singlet, t = triplet. Coupling constants, J, are recorded in Hertz (Hz). High resolution 
mass spectrometry (ESI) was performed using a Waters API Q-TOF Ultima instrument while low 
resolution mass spectrometry (LRMS) (EI+) was performed on a JEOL GC Mate III spectrometer. 
Analytical thin-layer chromatography (TLC) was performed on aluminium-backed silica-gel 60 
F254 (70-230 mesh) plates. Column chromatography was performed with Merck silica-gel 60 (70-
230 mesh).  Purity was determined by HPLC and all compounds were confirmed to have > 95% 
purity. 
  
4.1.2 General procedure for the synthesis of chloroquinolinylbenzoxazolamines 
Potassium ethyl xanthate (1872.4 mg, 11.7 mmol, 2 eq) was added to a solution of 2-amino-4-
nitrophenol or 2-amino-4-chloronitrophenol (5.8 mmol, 1 eq) in 25 ml of absolute ethanol. The 
reaction was heated at reflux for 4 h. The reaction mixture was then cooled to room temperature 
and concentrated to dryness under vacuum. The residue was dissolved in water and acidified to 
pH 5 using acetic acid. The resulting precipitate was filtered, washed with water and dried for 48 
h to give the products which were used without further purification. Iodomethane (1.2 eq) and 
anhydrous potassium carbonate (1 eq) were added to a solution of 5-nitrobenzoxazole-2-thiol or 
5-chlorobenzoxazole-2-thiol (1 eq) in acetonitrile (15 ml). The reaction mixture was stirred at 
room temperature for 4h. The reaction was quenched with a drop of water and the solvent removed 
under vacuum. The residue was suspended in water and extracted three times with ethyl acetate. 
The combined organic fractions were washed with brine (1×10ml) and dried over MgSO4. Solvent 
evaporation under vacuum yielded the products which were used without further purification. A 
mixture of 2-bromo-5-nitrobenzothiazole, 2-bromo-5-nitro-1H-benzimidazole, 2-bromo-5-
nitropyridine, 2-(methylthio)-5-nitrobenzoxazole, 5-chloro-2-(methylthio)-benzoxazole,  (1 eq) 
and the appropriate amine (3 eq) in acetonitrile was heated in a microwave reactor at 120 °C for 
20-30 min. The solvent was removed under vacuum and the residue dissolved in EtOAc, washed 
with water (2×10 ml), a solution of saturated NaHCO3 (only employed when bromo-substituted 
reactants were used to neutralize HBr), brine (10 ml) and dried over MgSO4. The solvent was 
removed under vacuum to obtain the products in crude mixture. Column chromatography using a 
MeOH: EtOAc (0-20%) (for tertiary amine products) or a hexane: EtOAc gradient afforded the 
pure products. The aromatic nitro-compound (1 mmol) was dissolved in ethanol (8 ml) with 
warming in a hydrogenator bottle. 10% Pd/C (0.3 times the weight of the compound being reduced) 
was added to this solution. The reaction bottle was sealed, filled with H2 and evacuated twice.  It 
was then shaken on a Parr shaker for 12 h at 60 psi of H2 until completion of the reaction 
(monitored by TLC). The reaction mixture was filtered through Celite and the solvent removed 
under vacuum to obtain the aromatic amine. The aromatic amine (1 mmol, 1 eq) was mixed with 
4,7-dichloroquinoline (1.1 eq) in acetonitrile (25 ml). The mixture was acidified with 3-5 drops of 
HCl and stirred at reflux for 24 h. The solvent was removed under vacuum after which the residue 
was dissolved in EtOAc (or 20% methanol in dichloromethane for tertiary amine compounds) and 
washed with saturated NaHCO3 (3×20 ml) and brine (1×10ml). The combined organic fractions 
were dried over anhydrous MgSO4, adsorbed onto silica gel (5g) and subjected to silica gel column 
chromatography to afford the target compounds.  
4.1.2.1.  N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyrrolidin-1-yl)ethyl)-benzoxazole-2,5-diamine, 19 
61 % yield. mp 98-102 °C. 1H NMR (400 MHz, CD3OD) δ 8.26 (d, J = 5.6 Hz, 1H), 8.21 (d, J = 
9.0 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.40 (dd, J = 9.0, 2.2 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.20 
(d, J = 2.1 Hz, 1H), 6.96 (dd, J = 8.4, 2.1 Hz, 1H), 6.70 (d, J = 5.6 Hz, 1H),  3.52 (t, J = 6.7 Hz, 
2H), 2.74 (t, J = 6.7 Hz, 2H), 2.58 (m, 4H), 1.77 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 163.56, 
150.98, 150.62, 148.76, 146.07, 143.68, 135.85, 135.24, 126.40, 125.12, 123.18, 117.87, 117.19, 
111.62, 108.76, 100.79, 54.72, 53.66, 41.21 (×2), 22.88 (×2). Anal. RP-HPLC tR = 8.64 min 
(method D, purity 97%). HRMS (ESI+): m/z = 408.1577 (exact mass for C22H22N5OCl = 
408.1591). 
 
4.1.2.2. 1-(3-(5-(7-Chloroquinolin-4-ylamino)benzoxazol-2-ylamino)propyl)pyrrolidin-2-one, 
22  
65 % yield. mp 95-97 °C. 1H NMR (400 MHz, CDCl3) δ 8.39 (d, J=5.5 Hz, 1H), 8.02 (d, J=9.0 
Hz, 1H), 7.98 (d, J=2.1 Hz, 1H), 7.40 (dd, J=9.0, 2.1 Hz, 1H), 7.24 (d, J=2.0 Hz, 1H), 7.19 (d, 
J=8.4 Hz, 1H), 6.92 (dd, J=8.4, 2.0 Hz, 1H), 6.72 (d, J=5.5 Hz, 1H), 3.34 - 3.45 (m, 6H), 2.42 (t, 
J=8.1 Hz, 2H), 2.14 – 1.99 (m, 2H), 1.93 – 1.80 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 176.16, 
163.15, 150.70, 149.82, 148.38, 146.55, 144.51, 135.64, 135.04, 127.68, 125.94, 122.00, 117.54, 
117.15, 112.39, 109.20, 101.52, 47.50, 39.57, 39.53, 30.89, 26.44, 17.95. Anal. RP-HPLC tR = 
9.95 min (method B, purity 97%). LRMS (EI+): m/z = 435.1 (exact mass for C23H22ClN5O2 = 
435.1462). 
 
4.1.2.3.   N5-(7-Chloroquinolin-4-yl)-N2-(2-(piperidin-1-yl)ethyl)benzoxazole-2,5-diamine, 23 
69 % yield. mp 89-91 °C. 1H NMR (400 MHz, CD3OD) δ 8.28 (d, J=5.6 Hz, 1H), 8.24 (d, J=9.0 
Hz, 1H), 7.81 (d, J=2.2 Hz, 1H), 7.43 (dd, J=9.0, 2.2 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 7.22 (d, 
J=2.1 Hz, 1H), 6.99 (dd, J=8.4, 2.2 Hz, 1H), 6.73 (d, J=5.6 Hz, 1H), 3.54 (t, J=6.7 Hz, 2H), 2.63 
(t, J=6.7 Hz, 2H), 2.56 – 2.42 (m, 4H), 1.66 – 1.53 (m, 4H), 1.49 – 1.40 (m, 2H); 13C NMR (101 
MHz, CD3OD) δ 163.59, 150.92, 150.68, 148.69, 146.09, 143.65, 135.85, 135.29, 126.35, 125.16, 
123.21, 117.87, 117.24, 111.64, 108.80, 100.79, 57.46, 54.16, 39.34, 25.14, 23.68. Anal. RP-
HPLC tR = 8.79 min (method A, purity >99%). LRMS (EI+): m/z = 421.1 (exact mass for 
C18H17N3O3S = 421.1669). 
 
4.1.2.4.   N5-(7-Chloroquinolin-4-yl)-N2-(3-(piperidin-1-yl)propyl)benzoxazole-2,5-diamine, 24  
 
58 % yield. mp 87-89 °C. 1H NMR (300 MHz, CD3OD) δ 8.26 (d, J=5.6 Hz, 1H), 8.21 (d, J=9.0 
Hz, 1H), 7.79 (d, J=2.2 Hz, 1H), 7.39 (dd, J=9.0, 2.2 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 7.20 (d, 
J=2.1 Hz, 1H), 6.96 (dd, J=8.4, 2.1 Hz, 1H), 6.71 (d, J=5.6 Hz, 1H), 3.39 (t, J=6.8 Hz, 2H), 2.45 
– 2.32 (m, 6H), 1.93 – 1.75 (m, 2H), 1.63 – 1.49 (m, 4H), 1.48 – 1.34 (m, 2H). 13C NMR (101 
MHz, CD3OD) δ 163.66, 151.02, 150.77, 148.80, 146.08, 143.70, 135.89, 135.28, 126.40, 125.16, 
123.22, 117.90, 117.28, 111.62, 108.77, 100.81, 56.38, 54.12, 41.03, 25.76, 25.18, 23.79. Anal. 
RP-HPLC tR = 9.11 min (method A, purity >99%). LRMS (EI+): m/z = 435.1 (exact mass for 
C24H26ClN5O = 435.1826). 
 
4.1.2.5.   N5-(7-Chloroquinolin-4-yl)-N2-(2-morpholinoethyl)benzoxazole-2,5-diamine, 25 
57 % yield. mp 107-109 °C. 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J=5.8 Hz, 1H), 8.07 (d, J=9.2 
Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.36 (dd, J=9.2, 2.0 Hz, 1H), 7.20 (d, J=2.2 Hz, 1H), 7.16 (d, 
J=8.4 Hz, 1H), 6.92 (dd, J=8.4, 2.2 Hz, 1H), 6.65 (d, J=5.8 Hz, 1H), 3.57 – 3.74 (m, 4H), 3.49 (t, 
J=5.8 Hz, 2H), 2.61 (t, J=5.8 Hz, 2H), 2.43 – 2.50 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 163.00, 
150.75, 149.81, 148.45, 146.48, 144.35, 135.59, 135.27, 127.59, 125.87, 122.10, 117.60, 117.28, 
112.47, 109.23, 101.53, 66.84 (×2), 56.86, 53.30, 39.14 (×2). Anal. RP-HPLC tR = 2.82 min 
(method C, purity >99%). LRMS (EI+): m/z = 423.0 (exact mass for C22H22N5O2Cl = 423.1462). 
 
4.1.2.6.   N5-(7-Chloroquinolin-4-yl)-N2-(3-morpholinopropyl)benzoxazole-2,5-diamine, 26 
53 % yield. mp 182-183 °C. 1H NMR (300 MHz, CD3OD) δ 8.28 (d, J=5.6 Hz, 1H), 8.23 (d, J=9.0 
Hz, 1H), 7.81 (d, J=2.2 Hz, 1H), 7.42 (dd, J=9.0, 2.2 Hz, 1H), 7.26 (d, J=8.4 Hz, 1H), 7.21 (d, 
J=2.1 Hz, 1H), 6.98 (dd, J=8.4, 2.1 Hz, 1H), 6.72 (d, J=5.6 Hz, 1H), 3.74 – 3.62 (m, 4H), 3.53 (t, 
J=6.6 Hz, 2H), 3.43 (t, J=6.6 Hz, 2H), 2.51 – 2.37 (m, 4H), 1.91 – 1.78 (m, 2H). 13C NMR (101 
MHz, CD3OD) δ 163.63, 150.96, 150.64, 148.73, 146.01, 143.70, 135.85, 135.25, 126.39, 125.14, 
123.19, 117.88, 117.15, 111.55, 108.74, 100.80, 66.35, 56.04, 53.38, 40.88, 25.58. Anal. RP-
HPLC tR = 11.52 min (method A, purity >99%). LRMS (EI+): m/z = 437.1 (exact mass for 
C23H24ClN5O = 437.1619). 
 
4.1.2.7.   N5-(7-Chloroquinolin-4-yl)-N2-(2-(diethylamino)ethyl)benzoxazole-2,5-diamine, 27 
61 % yield. mp 91-93 °C. 1H NMR (300 MHz, CD3OD) δ 8.27 (d, J=5.6 Hz, 1H), 8.23 (d, J=9.0 
Hz, 1H), 7.80 (d, J=2.2 Hz, 1H), 7.42 (dd, J=9.0, 2.2 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 7.21 (d, 
J=2.1 Hz, 1H), 6.98 (dd, J=8.4, 2.1 Hz, 1H), 6.72 (d, J=5.6 Hz, 1H), 3.49 (t, J=6.9 Hz, 2H), 2.73 
(t, J=6.9 Hz, 2H), 2.61 (q, J=7.2 Hz, 4H), 1.05 (t, J=7.2 Hz, 6H). 13C NMR (101 MHz, CD3OD) δ 
163.62, 150.97, 150.67, 148.75, 146.10, 143.71, 135.87, 135.26, 126.39, 125.14, 123.20, 117.89, 
117.23, 111.66, 108.78, 100.80, 51.44, 46.78, 39.97, 10.29. Anal. RP-HPLC tR = 11.34 min 
(method A, purity >99%). LRMS (EI+): m/z = 409.2 (exact mass for C22H24ClN5O = 409.1669). 
 
 4.1.2.8.   N5-(7-Chloroquinolin-4-yl)-N2-(3-(diethylamino)propyl)benzoxazole-2,5-diamine, 28 
46 % yield. mp 79-80 °C. 1H NMR  (400 MHz, CD3OD) δ 8.25 (d, J=5.6 Hz, 1H), 8.21 (d, J=9.0 
Hz, 1H), 7.78 (d, J=2.2 Hz, 1H), 7.37 (dd, J=9.0, 2.2 Hz, 1H), 7.23 (d, J=8.4 Hz, 1H), 7.20 (d, 
J=2.2 Hz, 1H), 6.95 (dd, J=8.4, 2.2 Hz, 1H), 6.70 (d, J=5.6 Hz, 1H), 3.40 (t, J=6.8 Hz, 2H), 2.68 
– 2.45 (m, 6H), 1.92 – 1.71 (m, 2H), 1.02 (t, J=7.2 Hz, 6H). 13C NMR (101 MHz, CD3OD) δ 
163.58, 150.95, 150.53, 148.73, 145.96, 143.65, 135.83, 135.21, 126.42, 125.11, 123.20, 117.87, 
117.08, 111.49, 108.74, 100.78, 49.96, 46.46, 41.03, 25.60, 9.98. Anal. RP-HPLC tR = 9.02 min 
(method A, purity >99%). LRMS (EI+): m/z = 423.2 (exact mass for C23H26ClN5O = 423.1826). 
 
4.1.2.9.   N5-(7-Chloroquinolin-4-yl)-N2-(2-(dimethylamino)ethyl)benzoxazole-2,5-diamine, 29 
44 % yield. 1H NMR (300 MHz, CD3OD) δ 8.30 (d, J=5.6 Hz, 1H), 8.26 (d, J=9.0 Hz, 1H), 7.83 
(d, J=2.2 Hz, 1H), 7.46 (dd, J=9.0, 2.2 Hz, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.23 (d, J=2.2 Hz, 1H), 
7.01 (dd, J=8.4, 2.2 Hz, 1H), 6.74 (d, J=5.6 Hz, 1H), 3.54 (t, J=6.6 Hz, 2H), 2.65 (t, J=6.6 Hz, 
2H), 2.33 (s, 6H). 13C NMR (101 MHz, CD3OD) δ 163.61, 150.90, 150.80, 148.67, 146.16, 143.68, 
135.86, 135.33, 126.31, 125.18, 123.23, 117.87, 117.35, 111.73, 108.82, 100.80, 57.72, 44.11, 
39.96. Anal. RP-HPLC tR = 8.56 min (method B, purity 99%). LRMS (EI+): m/z = 381.1 (exact 
mass for C20H20ClN5O = 381.1356). 
 
4.1.2.10. N5-(7-Chloroquinolin-4-yl)-N2-(3-(dimethylamino)propyl)benzoxazole-2,5-diamine, 
30 
52 % yield. mp 55-56 °C. 1H NMR (400 MHz, CD3OD) δ 8.28 (d, J=5.6 Hz, 1H), 8.24 (d, J=9.0 
Hz, 1H), 7.81 (d, J=2.2 Hz, 1H), 7.43 (dd, J=9.0, 2.2 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 7.22 (d, 
J=2.0 Hz, 1H), 6.99 (dd, J=8.4, 2.1 Hz, 1H), 6.72 (d, J=5.6 Hz, 1H), 3.43 (t, J=6.9 Hz, 2H), 2.53 
(t, J=7.7 Hz, 2H), 2.33 (s, 6H), 1.92 – 1.85 (m, 2H). 13C NMR (101 MHz, CD3OD) δ 163.64, 
150.90, 150.71, 148.67, 146.06, 143.65, 135.84, 135.29, 126.32, 125.16, 123.23, 117.86, 117.25, 
111.61, 108.79, 100.79, 56.42, 43.81 (×2), 40.55, 26.43. Anal. RP-HPLC tR = 2.65 min (method 
C, purity 95%). LRMS (EI+): m/z = 395.1 (exact mass for C21H22ClN5O = 395.1513). 
 
4.1.2.11.    N2-(3-Chlorobenzyl)-N5-(7-chloroquinolin-4-yl)benzoxazole-2,5-diamine, 31 
39 % yield. mp 98-99 °C. 1H NMR (400 MHz, CDCl3) δ 8.50 (d, J=5.4 Hz, 1H), 8.04 (d, J=2.1 
Hz, 1H), 7.91 (d, J=9.0 Hz, 1H), 7.46 (dd, J=9.0, 2.1 Hz, 1H), 7.41 (s, 1H), 7.34 – 7.23 (m, 5H), 
7.00 (dd, J=8.4, 2.1 Hz, 2H), 6.79 (d, J=5.4 Hz, 1H), 4.70 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
162.75, 151.79, 149.63, 148.84, 146.65, 144.40, 139.63, 135.77, 135.28, 130.07, 128.98, 128.10, 
127.75, 127.65, 125.92, 125.58, 121.06, 117.49, 112.87, 109.42, 102.10, 46.63. Anal. RP-HPLC 
tR = 13.93 min (method A, purity >99%). LRMS (EI+): m/z = 434.0 (exact mass for C23H16Cl2N4O 
= 434.0701). 
 
4.1.2.12. N5-(7-Chloroquinolin-4-yl)-N2-(3-(trifluoromethyl)benzyl)benzoxazole-2,5-diamine, 
32 
43 % yield. mp 108-110 °C. 1H NMR (400 MHz, CD3OD) δ 8.31 (d, J=5.6 Hz, 1H), 8.26 (d, J=9.0 
Hz, 1H), 7.84 (d, J=2.2 Hz, 1H), 7.73 – 7.70 (m, 1H), 7.69 – 7.65 (m, 1H), 7.60 – 7.51 (m, 2H), 
7.46 (dd, J=9.0, 2.2 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.24 (d, J=2.1 Hz, 1H), 7.04 (dd, J=8.4, 2.1 
Hz, 1H), 6.75 (d, J=5.6 Hz, 1H), 4.67 (s, 2H). 13C NMR (101 MHz, CD3OD) δ 163.62, 150.99, 
150.75, 148.75, 146.22, 143.50, 139.81, 136.00, 135.30, 130.69, 129.06, 126.35, 125.17, 123.89, 
123.85, 123.81, 123.63, 123.59, 123.21, 117.89, 117.59, 111.90, 108.95, 100.84, 45.41. Anal. RP-
HPLC tR = 14.84 min (method A, purity >99%). LRMS (EI+): m/z = 468.1 (exact mass for 
C24H16ClF3N4O = 468.0965). 
 
4.1.2.13.    N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-2-ylmethyl)benzoxazole-2,5-diamine, 33 
61 % yield. mp 118-120 °C. 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J=4.7 Hz, 1H), 8.41 (d, J=5.5 
Hz, 1H), 7.99 (d, J=2.0 Hz, 1H), 7.97 (d, J=9.0 Hz, 1H), 7.69 (td, J=7.8 (×2), 1.8 Hz, 1H), 7.40 
(dd, J=9.0, 2.0 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.29 (d, J=2.0 Hz, 1H), 7.20 – 7.26 (m, 2H), 6.95 
(dd, J=8.4, 2.0 Hz, 1H), 6.74 (d, J=5.5 Hz, 1H), 4.78 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
162.96, 155.51, 151.22, 149.33, 149.14, 149.01, 146.84, 144.63, 136.79, 135.50, 135.38, 128.40, 
125.96, 122.62, 121.76, 121.40, 117.66, 117.37, 112.80, 109.34, 101.89, 47.47. Anal. RP-HPLC 
tR = 11.29 min (method A, purity >99%). LRMS (EI+): m/z = 400.9 (exact mass for C22H16ClN5O 
= 401.1043). 
 
4.1.2.14.   N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyridin-2-yl)ethyl)benzoxazole-2,5-diamine, 34 
67 % yield. mp 89-91 °C. 1H NMR  (400 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.52 – 8.47 (m, 1H), 
8.42 (d, J=9.0 Hz, 1H), 8.38 (d, J=5.4 Hz, 1H), 8.06 (t, J=5.7 Hz, 1H), 7.85 (d, J=2.2 Hz, 1H), 
7.69 (td, J=7.8 (×2), 1.9 Hz, 1H), 7.52 (dd, J=9.0, 2.2 Hz, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.29 (d, 
J=7.8 Hz, 1H), 7.24 – 7.17 (m, 2H), 6.93 (dd, J=8.4, 2.1 Hz, 1H), 6.70 (d, J=5.4 Hz, 1H), 3.74 – 
3.63 (m, 2H), 3.07 (t, J=7.2 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 163.51, 159.25, 152.31, 
149.90, 149.81, 149.57, 145.97, 144.88, 136.94, 136.21, 134.28, 128.01, 125.15, 124.85, 123.76, 
122.04, 118.41, 116.89, 112.08, 109.31, 101.54, 42.53, 37.56. Anal. RP-HPLC tR = 13.20 min 
(method A, purity >99%). LRMS (EI+): m/z = 415.1 (exact mass for C23H18ClN5O = 415.1200). 
 
4.1.2.15.   N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-3-ylmethyl)benzo[d]oxazole-2,5-diamine, 35 
58 % yield. mp 108-109 °C. 1H NMR (400 MHz, CDCl3) δ 8.66 (d, J=2.2 Hz, 1H), 8.54 (dd, J=4.8, 
1.6 Hz, 1H), 8.46 (d, J=5.4 Hz, 1H), 8.00 (d, J=2.1 Hz, 1H), 7.90 (d, J=9.0 Hz, 1H), 7.78 – 7.71 
(m, 1H), 7.42 (dd, J=9.0, 2.2 Hz, 1H), 7.30 – 7.25 (m, 2H), 7.24 (d, J=2.2 Hz, 1H), 6.96 (dd, J=8.4, 
2.2 Hz, 1H), 6.76 (d, J=5.4 Hz, 1H), 4.70 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 162.66, 151.84, 
149.66, 149.40, 149.19, 148.79, 146.63, 144.29, 135.79, 135.26, 133.17, 129.01, 125.92, 123.58, 
121.07, 117.79, 117.58, 112.90, 109.47, 102.08, 77.25, 76.93, 76.61, 44.76. Anal. RP-HPLC tR = 
10.87 min (method A, purity >99%). LRMS (EI+): m/z = 401.1 (exact mass for C22H16ClN5O = 
401.1043). 
 
4.1.2.16.   N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-4-ylmethyl)benzoxazole-2,5-diamine, 36 
23 % yield. mp 202-204 °C. 1H NMR (300 MHz, CD3OD) δ 8.52 – 8.43 (m, 2H), 8.31 (d, J=5.6 
Hz, 1H), 8.27 (d, J=9.0 Hz, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.51 – 7.42 (m, 1H, 3H), 7.36 (d, J=8.4 
Hz, 1H), 7.23 (d, J=2.1 Hz, 1H), 7.05 (dd, J=8.4, 2.1 Hz, 1H), 6.75 (d, J=5.6 Hz, 1H), 4.67 (s, 2H). 
13C NMR (101 MHz, CD3OD) δ 163.58, 150.96, 150.78, 149.12, 148.86, 148.72, 146.29, 143.44, 
136.05, 135.34, 126.33, 125.20, 123.22, 122.26, 117.89, 117.72, 111.99, 109.03, 100.83, 44.73. 
Anal. RP-HPLC tR = 10.06 min (method B, purity 96%). LRMS (EI+): m/z = 401.1 (exact mass 
for C22H16ClN5O = 401.1043). 
 
4.1.2.17.   N5-(7-Chloroquinolin-4-yl)-N2-(4-methylpiperazin-1-yl)benzoxazole-2,5-diamine, 37 
49 % yield. mp 80-81 °C. 1H NMR (400 MHz, CD3OD) δ 8.29 (d, J=5.6 Hz, 1H), 8.25 (d, J=9.0 
Hz, 1H), 7.82 (d, J=2.1 Hz, 1H), 7.44 (dd, J=9.0, 2.1 Hz, 1H), 7.34 (d, J=8.5 Hz, 1H), 7.25 (d, 
J=2.1 Hz, 1H), 7.03 (dd, J=8.5, 2.1 Hz, 1H), 6.74 (d, J=5.6 Hz, 1H), 3.75 – 3.64 (m, 4H), 2.60 – 
2.51 (m, 4H), 2.33 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 163.15, 151.79, 149.49, 149.08, 146.81, 
145.15, 135.31, 135.17, 128.76, 127.75, 125.76, 121.39, 116.30, 112.03, 109.01, 101.85, 43.05 
(×2), 13.46 (×2). Anal. RP-HPLC tR = 8.87 min (method A, purity >99%). LRMS (EI+): m/z = 
408.1 (exact mass for C21H21ClN6O = 408.1465). 
 
4.1.2.18.   N5-(7-Chloroquinolin-4-yl)-N2,N2-diethylbenzoxazole-2,5-diamine, 38 
58 % yield. mp 189-190 °C. 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J=5.4 Hz, 1H), 7.99 (d, J=2.2 
Hz, 1H), 7.90 (d, J=8.9 Hz, 1H), 7.39 (dd, J=8.9, 2.2 Hz, 1H), 7.23 – 7.25 (m, 2H), 6.88 (dd, J=8.3, 
2.2 Hz, 1H), 6.76 (d, J=5.4 Hz, 1H), 3.59 (q, J=7.2 Hz, 4H), 1.29 (t, J=7.2 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 163.15, 151.79, 151.67, 149.49, 149.08, 146.81, 145.15, 135.31, 135.17, 128.76, 
125.76, 121.39, 116.30, 112.03, 109.01, 101.85, 43.05 (×2), 13.46 (×2). Anal. RP-HPLC tR = 12.97 
min (method A, purity >99%). LRMS (EI+): m/z = 366.1 (exact mass for C20H19ClN4O = 
366.1247). 
 
4.1.2.19.   N-(7-Chloroquinolin-4-yl)-2-(4-methylpiperazin-1-yl)benzoxazol-5-amine, 39 
47 % yield. mp 113-115 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 8.41 (d, J=9.0 Hz, 
1H), 8.38 (d, J=5.4 Hz, 1H), 7.85 (d, J=2.2 Hz, 1H), 7.52 (dd, J=9.0, 2.2 Hz, 1H), 7.43 (d, J=8.2 
Hz, 1H), 7.23 (d, J=2.0 Hz, 1H), 6.98 (dd, J=8.2, 2.0 Hz, 1H), 6.70 (d, J=5.4 Hz, 1H), 3.60 (t, 
J=5.0 Hz, 4H), 2.42 (t, J=5.0 Hz, 4H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.04, 
152.38, 150.03, 149.68, 146.20, 144.55, 136.64, 134.27, 128.10, 125.15, 124.82, 118.49, 117.21, 
112.20, 109.72, 101.64, 54.18, 46.21, 45.66. Anal. RP-HPLC tR = 11.50 min (method A, purity 
>99%). LRMS (EI+): m/z = 393.1 (exact mass for C21H20ClN5O = 393.1356). 
 
4.1.2.20.   N-(7-Chloroquinolin-4-yl)-2-(4-phenylpiperazin-1-yl)benzoxazol-5-amine, 40 
74 % yield. mp 96-98 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.42 (d, J=9.0 Hz, 1H), 
8.39 (d, J=5.3 Hz, 1H), 7.86 (d, J=2.2 Hz, 1H), 7.52 (dd, J=9.0, 2.2 Hz, 1H), 7.45 (d, J=8.4 Hz, 
1H), 7.29 – 7.16 (m, 3H), 7.05 – 6.94 (m, 3H), 6.82 (t, J=7.2 Hz, 1H), 6.72 (d, J=5.3 Hz, 1H), 3.75 
(t, J=5.0 Hz, 4H), 3.27 (t, J=5.0 Hz, 4H). 13C NMR (101 MHz, DMSO-d6) δ 163.07, 152.34, 
151.29, 150.17, 149.80, 146.38, 144.64, 136.96, 134.29, 129.46, 128.17, 125.08, 124.80, 119.98, 
118.68, 117.29, 116.60, 112.33, 109.69, 101.94, 48.52, 45.73. Anal. RP-HPLC tR = 15.41 min 
(method A, purity >99%). LRMS (EI+): m/z = 455.1 (exact mass for C26H22ClN5O = 455.1513). 
 
4.1.2.21.   2-(4-(3-Chlorophenyl)piperazin-1-yl)-N-(7-chloroquinolin-4-yl)benzoxazol-5-amine, 
41 
40 % yield. mp 90-92 °C. 1H NMR (400 MHz, CDCl3) δ 8.46 (d, J=5.3 Hz, 1H), 8.00 (d, J=2.1 
Hz, 1H), 7.89 (d, J=9.0 Hz, 1H), 7.40 (dd, J=9.0, 2.1 Hz, 1H), 7.31 – 7.25 (m, 2H), 7.24 – 7.15 
(m, 1H), 6.95 (dd, J=8.4, 2.1 Hz, 1H), 6.92 (t, J=2.2 Hz, 1H), 6.89 – 6.86 (m, 1H), 6.84 – 6.80 (m, 
1H),  6.77 (d, J=5.4 Hz, 1H), 3.92 – 3.80 (m, 4H), 3.38 – 3.22 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 162.89, 152.03, 151.82, 149.68, 148.89, 146.77, 144.54, 135.89, 135.21, 130.16, 128.93, 
125.82, 121.22, 120.45, 117.86, 117.19, 116.73, 114.69, 112.61, 109.36, 102.07, 48.67, 45.47. 
Anal. RP-HPLC tR = 15.94 min (method A, purity >99%). LRMS (EI+): m/z = 489.1 (exact mass 
for C26H21Cl2N5O = 489.1123). 
 
4.1.2.22.   N-(7-Chloroquinolin-4-yl)-2-((dimethylamino)methyl)benzoxazol-5-amine, 42 
49 % yield. mp 156-158 °C. 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 5.4 Hz, 1H), 7.88 – 7.94 
(m, 1H, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 9.0, 2.2 Hz, 1H), 7.21 
(dd, J = 8.6, 2.1 Hz, 1H), 6.68 (d, J = 5.4 Hz, 1H), 3.73 (s, 2H), 2.34 (s, 6H). 13C NMR (101 MHz, 
CD3OD) δ 164.75, 151.11, 150.36, 148.82, 148.48, 141.53, 136.86, 135.39, 126.47, 125.36, 
123.21, 122.28, 118.03, 115.03, 111.18, 100.96, 55.09, 44.04. Anal. RP-HPLC tR = 2.78 min 
(method C, purity 98%). LRMS (EI+): m/z = 352.0 (exact mass for C19H17ClN4O = 352.1091). 
 
4.1.2.23.   N-(7-Chloroquinolin-4-yl)-2-(2-methoxyethyl)benzoxazol-5-amine, 43 
65 % yield. mp 165-166 °C. 1H NMR (300 MHz, CD3OD) δ 8.33 (d, J=5.5 Hz, 1H), 8.27 (d, J=9.0 
Hz, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.63 – 7.59 (m, 2H), 7.47 (dd, J=9.0, 2.2 Hz, 1H), 7.35 (dd, J=8.6, 
2.2 Hz, 1H), 6.77 (d, J=5.5 Hz, 1H), 3.89 (t, J=6.2 Hz, 2H), 3.37 (s, 3H), 3.21 (t, J=6.2 Hz, 2H). 
13C NMR (101 MHz, CD3OD) δ 167.58, 156.58, 150.21, 142.90, 142.26, 140.17, 139.21, 133.37, 
127.89, 124.91, 122.88, 119.14, 116.70, 115.91, 111.71, 100.24, 68.50, 57.54, 28.89. Anal. RP-
HPLC tR = 12.83 min (method A, purity >99%). LRMS (EI+): m/z = 353.1 (exact mass for 
C19H16ClN3O2 = 353.0931). 
 
 
 
 
4.2. In vitro P. falciparum assay and in vivo antimalarial efficacy studies.  
Compounds were screened against multidrug resistant (K1) and sensitive (NF54) strains of P. 
falciparum in vitro using the modified [3H]-hypoxanthine incorporation assay.36 In vivo efficacy 
was conducted as previously described,37 with the modification that mice (n = 3) were infected 
with a GFP-transfected P. berghei ANKA strain (donated by A. P. Waters and C. J. Janse, Leiden 
University, The Netherlands), and parasitemia was determined using standard flow cytometry 
techniques. The detection limit was 1 parasite in 1,000 erythrocytes (that is, 0.1%). Activity was 
calculated as the difference between the mean per cent parasitaemia for the control and treated 
groups expressed as a per cent relative to the control group. Compounds were dissolved or 
suspended in 70/30 Tween 80/ethanol, diluted 10× with water and orally administered once per 
day on four consecutive days (4, 24, 48 and 72 h after infection). Blood samples for the quadruple-
dose regimens were collected on day 4 (96 h after infection).  
 
 
4.3. β-Hematin formation inhibition assay 
The β-hematin formation inhibition assay method described by Carter et al. was modified for 
manual liquid delivery 38,39. Two stock solutions of the samples were prepared by dissolving the 
pre-weighed compound in DMSO with sonication to give 20 mM and 2 mM solutions of each 
sample. These were delivered to a 96-well plate in duplicate to give concentrations ranging from 
0–1000 μM (final well concentration) with a total DMSO volume of 10 μL in each well, after 
which deionised 1HO (70 μL) and NP-40 (20 μL; 30.55 μM) were added. Plates containing 
coloured compounds were pre-read on a on a SpectraMax plate reader for blanking purposes. A 
25 mM haematin stock solution was prepared by sonicating hemin in DMSO for one minute and 
then suspending 178 μL of this in 1M acetate buffer (pH 4.8). The homogenous suspension (100 
μL) was then added to the wells to give final buffer and hematin concentrations of 0.5 M and 100 
μM respectively. The plate was covered and incubated at 37°C for 5–6 hrs. Free heme was detected 
using the pyridine-ferrichrome method developed by Ncokazi and Egan 40. A solution of 50 % 
(v/v) pyridine, 30 % (v/v) 1HO, 20 % (v/v) acetone and 0.2 M HEPES buffer (pH 7.4) was prepared 
and 32 μL added to each well to give a final pyridine concentration of ~5 % (v/v). Acetone (60 
μL) was then added to assist with haematin dispersion. The UV-vis absorbance of the plate wells 
was read on a SpectraMax® 340 PC384 Absorbance Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA). Sigmoidal dose-response curves were fitted to the absorbance data using 
GraphPad Prism v3.02 to obtain a 50 % inhibitory concentration (IC50) for each compound. 
 
4.4. Cytotoxicity assay against CHO cells 
Test samples were screened for in vitro cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT)-assay. The MTT-assay is used as a colorimetric assay for cellular growth and survival, and 
compares well with other available assays.41,42 The tetrazolium salt MTT was used to measure all 
growth and chemosensitivity. Test samples were tested in triplicate on one occasion. The test 
samples were prepared to a 20 mg/ml stock solution in 100 % DMSO. Stock solutions were stored 
at -20ºC. Further dilutions were prepared in complete medium on the day of the experiment. 
Samples were tested as a suspension if not completely dissolved. Emetine was used as the reference 
drug in all experiments. The initial concentration of emetine was 100 μg/ml, which was serially 
diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 
μg/ml. The same dilution technique was applied to the all test samples. The highest concentration 
of solvent to which the cells were exposed to had no measurable effect on the cell viability (data 
not shown). The 50% inhibitory concentration (IC50) values were obtained from full dose-response 
curves, using a non-linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
 
4.5. Microsomal stability assay 
This assay was conducted in 96-well plate format according to a previously reported method.34 
Test compounds and controls were prepared from 10 mM DMSO stock solutions. 0.40 mg 
protein/ml microsomes (pooled Human mixed gender, male Mouse BALB/c) from XenoTech were 
incubated with 1 mM test compound at 37 °C. Metabolic reactions were initiated by the addition 
of the co-factor NADPH and the plates were incubated for 30 minutes. The reactions were 
quenched with triple the volume of acetonitrile containing carbamazepine as internal standard. The 
centrifuged and filtered samples were analyzed by HPLC-MS/MS using either a Micromass single 
quadrupole, triple quadrupole or TOF mass spectrometer (Waters Corporation, Milford, MA) to 
determine the remaining concentrations of the test compounds. Control standards (midazolam and 
propranolol) were included in the assay to provide quality control and an indication of the 
metabolic capacity of the microsomes used. 
 
 
4.6. Pharmacokinetic evaluation in mice 
In vivo pharmacokinetics was analysed in six, 8-week-old male C57BL/6 mice divided into an 
intravenous and oral dosage group, n = 3. After a single 5 mg/kg intravenous injection of 24 into 
the penile dorsal vein (formulation; DMSO, PEG, EtOH, PPG (2:6:1:7, v/v)), 20 µl of blood was 
collected from the tail tip at 0.08, 0.5, 1, 3, 7 and 24 h and stored at - 80°C. The oral groups received 
a single 20 mg/kg dose by oral gavage of the selected compound suspended in a 0.5% HPMC in 
water solution and blood collected was at 0.5, 1, 3, 5 and 24 h. Whole blood concentration of the 
compounds were quantified by an LC-MS/MS assay developed for a range of 10 – 5000 ng/ml. 
The samples were extracted by protein precipitation using 20 µl whole blood and 80 µl methanol. 
Gradient chromatography was performed on a Waters Xterra™ MS C18 (2.1 × 30mm, 3.5 µm) 
reverse phase column with mobile phase 0.1% ammonium hydroxide:water (v/v) and 0.1% 
ammonium hydroxide:acetonitrile (v/v) at a flow rate of 400 µl/min. An AB Sciex API 3200 mass 
spectrometer was operated at unit resolution in multiple reaction monitoring mode, monitoring the 
transitions of the protonated molecular ions to its product ion of 436.3 → 351.2. The accuracies 
(%Nom) were between 88.1% and 109.3% at lowest level of quantification (10 ng/ml), medium 
(2000 ng/ml) and high (4000 ng/ml) quality controls. Non-compartmental analysis was performed 
on 24 using Summit PK solutions™ (Summit Research Services, Montrose, USA). 
 
SUPPLEMENTARY CONTENT:  
Supporting Information. HPLC conditions for purity checks, 1H-NMR spectra of selected 
compounds and additional compound data. 
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